Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Lenacapavir, Gilead Sciences’ (NASDAQ: GILD) innovative therapy for HIV pre-exposure prophylaxis (PrEP), is not only a breakthrough in clinical efficacy but also a model for advancing equitable ...

AstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to be that there would anyway be little value in such a deal. On Sunday ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Gilead's lenacapavir reduced HIV infections by 96% in Phase 3 trials, surpassing Truvada. Gilead plans to begin Phase 3 study for once-yearly lenacapavir in 2025, with regulatory filings in 2027 ...

Kathryn Hahn and J.K. Simmons are among the new cast members added to Season 3 of Kevin Hart’s “Die Hart.” Tony Cavalero and Anna Garcia have also joined the third installment of the action ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Still, in the U.S. alone, Gilead has an eye on the 44% of people with HIV who have not achieved viral suppression through PrEP and set a goal of cranking up the U.S. PrEP market to encompass more ...

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of ...